- Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort
- Effect of more vs less frequent follow-up testing on overall and colorectal cancer–specific mortality in patients with stage II or III colorectal cancer: The COLOFOL Randomized Clinical Trial
- Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer
- Effects of <em>Helicobacter pylori</em> eradication for metachronous gastric cancer prevention: A randomized controlled trial
- Intraoperative radiotherapy in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for pancreatic adenocarcinoma
- Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies
- Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis
- Presence of intratumoral calcifications and vasculature is associated with poor overall survival in clear cell renal cell carcinoma
- Phase II study of everolimus and octreotide LAR in patients with nonfunctioning gastrointestinal neuroendocrine tumors: The GETNE1003_EVERLAR study
- Assessing venous thrombus in renal cell carcinoma: Preliminary results for unenhanced 3D-SSFP MRI
- Determination of the mutational landscape in Taiwanese patients with papillary thyroid cancer by whole-exome sequencing
- Trends in the clinical presentation, treatment, and survival for pancreatic adenocarcinoma
- Application of Cu-64 NODAGA-PSMA PET in prostate cancer
- Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status
- Prophylactic cranial irradiation vs observation in radically treated stage III non–small-cell lung cancer: A randomized phase III NVALT-11/DLCRG-02 study
Feed Sources
